RenovoRx, Inc. (RNXT)
1.19
+0.07
(+6.25%)
USD |
NASDAQ |
Oct 15, 16:00
1.20
+0.01
(+0.84%)
After-Hours: 20:00
RenovoRx Research and Development Expense (Quarterly) : 1.20M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.20M |
| March 31, 2026 | 1.228M |
| December 31, 2025 | 1.501M |
| September 30, 2025 | 1.685M |
| June 30, 2025 | 1.426M |
| March 31, 2025 | 1.642M |
| December 31, 2024 | 1.576M |
| September 30, 2024 | 1.65M |
| June 30, 2024 | 1.542M |
| March 31, 2024 | 1.257M |
| December 31, 2023 | 0.775M |
| September 30, 2023 | 1.629M |
| June 30, 2023 | 1.925M |
| Date | Value |
|---|---|
| March 31, 2023 | 1.338M |
| December 31, 2022 | 0.776M |
| September 30, 2022 | 0.846M |
| June 30, 2022 | 1.39M |
| March 31, 2022 | 1.289M |
| December 31, 2021 | 1.101M |
| September 30, 2021 | 0.767M |
| June 30, 2021 | 0.536M |
| March 31, 2021 | 0.635M |
| September 30, 2020 | 0.727M |
| June 30, 2020 | 0.402M |
| March 31, 2020 | 0.805M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Enanta Pharmaceuticals, Inc. | 22.13M |
| Travere Therapeutics, Inc. | 60.28M |
| REGENXBIO, Inc. | 52.33M |
| Krystal Biotech, Inc. | 13.16M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |